



J.P Morgan Healthcare Conference January 12th, 2022

Lupin Limited Vinita Gupta, CEO







Materials and information provided during this presentation may contain 'forward-looking statements'. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.

Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents obtained by competitors. Challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.

Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance.


You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation.

The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.



Lupin Today





CY21 Highlights and Recent Performance

Increasing Sales Momentum: Achieved sustained guarterly revenue growth despite headwinds

Complex Gx Platform Successes: Inhalation and Biosimilars platforms continued scaling

- Albuterol reached 20%+ US generic market share. Authorized generic launch of Brovana in the US reached 50% share. Luforbec, gFostair launched in the UK.
- bEtanercept sales continued to grow in Europe and Japan. US BLA filed on Pegfilgrastim.

Novel Pipeline Progress: Received USD 50 million development milestones from BI on MEK Inhibitor. Lupin Oncology Inc created to advance pipeline of differentiated Oncology programs.

Gx Pipeline Progress: 19 filings with the US FDA in CY21 incl. 4 eFTF, bringing our total FTFs to 51


Rebuilding Quality Reputation: 17 positive outcomes on Major agency audits during CY20 & CY21 (USFDA, MHRA, PMDA, ANVISA, Cofepris)

- Received EIR from US FDA with Voluntary Action Indicated classification for Goa plant
- Track record of success on desktop audits from WHO and TGA

EBITDA Focus: Focus on pipeline monetization and cost optimization to enhance EBITDA

Navigating the COVID Era: Delivered our mission of ensuring the health and well-being of our people while maintaining our supply of life-saving medicines





H1 FY2022¹

(% of Global Net Sales)

Strategic Vision: Evolving and Growing Global Pharma Company



Highly scaled and Evolving Core Generics Businesses

Innovative Platforms

Strong Generics Foundation Amongst the Top 10 generic companies in the World	US Generics Growth driven by a diversified portfolio Execution on high- value opportunities	India Region Formulations Achieving Top 3 by share and building in select adjacencies	Other Growth Markets Grow Scale and Operating Leverage	Novel products: Specialty & NCE'sCanadian Specialty PlatformFocused Commercialization in GI (Zaxine) and Women's HealthEU Neurology
Evolving through Complex Generics Investing heavily in the development of high barrier therapeutics	Global Inhalation Platform Execution and scaling in our markets and beyond	Global Biosimilars Business Launch execution, Portfolio expansion and Development	Global Long Acting and US Gx Injectables Clinical execution and Scale	NaMuscla Geographic expansion and partnership US Women's Health Targeted operations with accretive portfolio expansion Novel Oncology Research Platform
	Integrated Glob	Pipeline acceleration		

Substantial and Growing position in developed markets



US Generics: Consolidating our position

#3

US Pharma Rank (by TRx)

165 Products

marketed

(cumulative)

29%

Average market share (marketed products)

119

Top 3 by market share (Number of products)

Top Product

(by Net Sales)

Albuterol


Canada: Rapid Branded and Generics growth

(Number of products)

58

Market

leader




Oral Contraceptive Lead Generic Portfolio

Europe: Expanding cGx and Specialty footprint

Luforbec (gFostair)	NaMuscla	Nepexto
Recent Complex product launch (in the UK)	non-Dystrophic Myotonia Orphan Drug (available in UK, DE, FR)	Biosimilar Etanercept (available in DE, FR, Belgium, Croatia, FIN)

Australia: Strong Organic and Inorganic Growth



Strong growth momentum in India and Other Emerging Markets



India Mexico 67% 21% #2 #2 22% 65% Growth H1 **Ophthalmic Ophthalmic Growth H1 Respiratorv** Chronic contribution FY22 YoY Rank **Rank in IPM** FY22 YoY contribution (Value) (to net sales) (by prescriptions) (IQVIA MAT Mar-21) (Value) (volume) Brazil Molnulup Diagnostics >30 Dipimed 30% #5 Most recently Molnupiravir In licensed Lead Brand **Brazil Generic OTC Portfolio** launched by Lupin in India brands (drops indicated as an (launched Jan 7) Pharma Rank Contribution adjacency analgesic and antipyretic) (15+ partners) (IQVIA Sept-21 Units) (by net sales)

South Africa




South Africa Generic Rank (by prescriptions)




Efferflu Immune Booster Largest product (Sales)

Philippines



#5 Philippines Branded Gx Rank (IQVIA MAT Jun-21)

7






Advancing our NCE Pipeline



Key Oncology Strategies

Oncology Pipeline Status



Improving our Quality scorecard and Delivering **Operational Efficiency gains**



Rebuilding Quality Reputation

	Agency	Site	Status		
FY20	USFDA	6 sites	Received EIR for 6 sites		
	Other	4 sites	GMP certificate valid for 3-5 years		
FY21	USFDA	Somerset	13 observations; Warning Letter in Q1 FY22		
	Cofepris Mexico	Laboratorios Grin	Received GMP certificate		
	WHO Geneva	Vizag Aurangabad Pithampur unit-2	GMP certificate issued for all sites		
	TGA Australia	Mandideep Unit-2 Dabhasa, Ankleshwar	GMP certificate issued		
		Mandideep Unit-1	Audit completed		
	EMA	Biotech, Pune	GMP certificate issued		
Υ22	USFDA	Goa	Q3 FY22 Inspection; VAI.		

Tarapur continues under US FDA OAI

Somerset, Pithampur Unit-2, and Mandideep Unit-1 continue under WL

Enhancing our operating margins

Strategic Focus	 Completed restructuring of US Women's Health / Specialty business Created Lupin Oncology Inc. around our Oncology NCE pipeline
nufacturing nd Supply Chain	 Ensuring robust supply chain continuity Integrated processes to improve OTIF, service levels, and other efficiency metrics Optimizing capacity utilization Accelerated roll-out of next generation processes and tools to improve

productivity


R&D Delivery

Mai

a

• Substantial Complex Generics new product launch calendar

10





Registered Office

Lupin Limited,

3rd Floor, Kalpataru Inspire, Off. Western Expressway Highway, Santacruz (East), Mumbai 400 055, India. Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051 | www.lupin.com





LupinWorld

